Anticancer agent and side-effect-alleviating agent

Patent metadata

Field	Value
Publication number	US-9907852-B2
Application number	US-201515302863-A
Country	US
Kind code	B2
Filing date	Apr 10, 2015
Priority date	Apr 10, 2014
Publication date	Mar 6, 2018
Grant date	Mar 6, 2018

Abstract

The purpose of the present invention is to provide an anticancer agent for potentiating an antitumor effect, alleviating side effects, and further extending the survival rate by concomitant use with a component having an anticancer effect. An anticancer agent combining arctigenin and a component other than arctigenin that has an anticancer effect, in which the anticancer agent may be a combination drug or may be a kit configured from a formulation containing arctigenin and a formulation containing a component that has an anticancer effect, and the concomitant use of arctigenin and the component having an anticancer effect more strongly inhibits tumor growth and reduces the proportion of cancer stem cells in the tumor, making it possible to extend the total survival time and to alleviate side effects caused by the component having an anticancer effect.

First claim

The invention claimed is:

1. A method for normalizing intra-tumor blood vessels in a subject in need thereof, the method comprising administering an effective dose of arctigenin to the subject, whereby intra tumor blood vessels are normalized.

2. A method for enhancing drug delivery of a component having an anticancer activity to a tumor tissue in a subject in need thereof, the method comprising administering an effective dose of arctigenin to the subject, whereby drug delivery to said tumor tissue is enhanced.

3. A method for alleviating a lowering of the weight/body weight rate (%) of liver and spleen or hepatopathy caused by a component having an anticancer activity other than arctigenin in a subject in need of thereof, comprising administering an effective dose of arctigenin to the subject, whereby said weight/body weight rate (%) of liver and/or spleen or hepatopathy is lowered.

4. The method of claim 1 , wherein the arctigenin is a Burdock fruit extract.

5. The method of claim 2 , wherein the arctigenin is a Burdock fruit extract.

6. The method of claim 3 , wherein the arctigenin is a Burdock fruit extract.

Assignees

• National Univ Corporation Univ Of Toyama
• Kracie Pharma Ltd
• Nat Cancer Ct
• Univ Tokyo Science Found

Inventors

• Esumi Hiroyasu
• Ikeda Masafumi
• Tsuchihara Katsuya
• Chiba Shigeki
• Yomoda Satoshi
• Kawashima Takanori
• Okubo Toshiki
• Tezuka Yasuhiro
• Murata Kenta

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/427

  not condensed and containing further heterocyclic rings · CPC title

• A61K47/46

  Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts · CPC title

• A61K39/3955

  against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title